Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk

E. Cantu, Y. Suzuki, J. M. Diamond, J. Ellis, J. Tiwari, B. Beduhn, J. R. Nellen, R. Shah, N. J. Meyer, D. J. Lederer, S. M. Kawut, S. M. Palmer, L. D. Snyder, M. G. Hartwig, V. N. Lama, S. Bhorade, M. Crespo, E. Demissie, K. Wille, J. OrensP. D. Shah, A. Weinacker, D. Weill, D. Wilkes, D. Roe, L. B. Ware, F. Wang, R. Feng, J. D. Christie

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The authors previously identified plasma plasminogen activator inhibitor-1 (PAI-1) level as a quantitative lung injury biomarker in primary graft dysfunction (PGD). They hypothesized that plasma levels of PAI-1 used as a quantitative trait could facilitate discovery of genetic loci important in PGD pathogenesis. A two-stage cohort study was performed. In stage 1, they tested associations of loci with PAI-1 plasma level using linear modeling. Genotyping was performed using the Illumina CVD Bead Chip v2. Loci meeting a p <5 × 10-4 cutoff were carried forward and tested in stage 2 for association with PGD. Two hundred ninety-seven enrollees were evaluated in stage 1. Six loci, associated with PAI-1, were carried forward to stage 2 and evaluated in 728 patients. rs3168046 (Toll interacting protein [TOLLIP]) was significantly associated with PGD (p = 0.006). The increased risk of PGD for carrying at least one copy of this variant was 11.7% (95% confidence interval 4.9-18.5%). The false-positive rate for individuals with this genotype who did not have PGD was 6.1%. Variants in the TOLLIP gene are associated with higher circulating PAI-1 plasma levels and validate for association with clinical PGD. A protein quantitative trait analysis for PGD risk prioritizes genetic variations in TOLLIP and supports a role for Toll-like receptors in PGD pathogenesis. Plasma plasminogen activator inhibitor-1 quantitative trait analysis prioritizes genetic variations in TOLLIP for posttransplant primary graft dysfunction and supports a role for Toll-like receptors in primary graft dysfunction pathogenesis.

Original languageEnglish (US)
Pages (from-to)833-840
Number of pages8
JournalAmerican Journal of Transplantation
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Primary Graft Dysfunction
Quantitative Trait Loci
Transplants
Lung
Plasminogen Activator Inhibitor 1
Proteins
Toll-Like Receptors
Genetic Loci
Lung Injury

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. / Cantu, E.; Suzuki, Y.; Diamond, J. M.; Ellis, J.; Tiwari, J.; Beduhn, B.; Nellen, J. R.; Shah, R.; Meyer, N. J.; Lederer, D. J.; Kawut, S. M.; Palmer, S. M.; Snyder, L. D.; Hartwig, M. G.; Lama, V. N.; Bhorade, S.; Crespo, M.; Demissie, E.; Wille, K.; Orens, J.; Shah, P. D.; Weinacker, A.; Weill, D.; Wilkes, D.; Roe, D.; Ware, L. B.; Wang, F.; Feng, R.; Christie, J. D.

In: American Journal of Transplantation, Vol. 16, No. 3, 01.03.2016, p. 833-840.

Research output: Contribution to journalArticle

Cantu, E, Suzuki, Y, Diamond, JM, Ellis, J, Tiwari, J, Beduhn, B, Nellen, JR, Shah, R, Meyer, NJ, Lederer, DJ, Kawut, SM, Palmer, SM, Snyder, LD, Hartwig, MG, Lama, VN, Bhorade, S, Crespo, M, Demissie, E, Wille, K, Orens, J, Shah, PD, Weinacker, A, Weill, D, Wilkes, D, Roe, D, Ware, LB, Wang, F, Feng, R & Christie, JD 2016, 'Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk', American Journal of Transplantation, vol. 16, no. 3, pp. 833-840. https://doi.org/10.1111/ajt.13525
Cantu, E. ; Suzuki, Y. ; Diamond, J. M. ; Ellis, J. ; Tiwari, J. ; Beduhn, B. ; Nellen, J. R. ; Shah, R. ; Meyer, N. J. ; Lederer, D. J. ; Kawut, S. M. ; Palmer, S. M. ; Snyder, L. D. ; Hartwig, M. G. ; Lama, V. N. ; Bhorade, S. ; Crespo, M. ; Demissie, E. ; Wille, K. ; Orens, J. ; Shah, P. D. ; Weinacker, A. ; Weill, D. ; Wilkes, D. ; Roe, D. ; Ware, L. B. ; Wang, F. ; Feng, R. ; Christie, J. D. / Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 3. pp. 833-840.
@article{7ff4f32ebcb545168b4c11001f0667cf,
title = "Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk",
abstract = "The authors previously identified plasma plasminogen activator inhibitor-1 (PAI-1) level as a quantitative lung injury biomarker in primary graft dysfunction (PGD). They hypothesized that plasma levels of PAI-1 used as a quantitative trait could facilitate discovery of genetic loci important in PGD pathogenesis. A two-stage cohort study was performed. In stage 1, they tested associations of loci with PAI-1 plasma level using linear modeling. Genotyping was performed using the Illumina CVD Bead Chip v2. Loci meeting a p <5 × 10-4 cutoff were carried forward and tested in stage 2 for association with PGD. Two hundred ninety-seven enrollees were evaluated in stage 1. Six loci, associated with PAI-1, were carried forward to stage 2 and evaluated in 728 patients. rs3168046 (Toll interacting protein [TOLLIP]) was significantly associated with PGD (p = 0.006). The increased risk of PGD for carrying at least one copy of this variant was 11.7{\%} (95{\%} confidence interval 4.9-18.5{\%}). The false-positive rate for individuals with this genotype who did not have PGD was 6.1{\%}. Variants in the TOLLIP gene are associated with higher circulating PAI-1 plasma levels and validate for association with clinical PGD. A protein quantitative trait analysis for PGD risk prioritizes genetic variations in TOLLIP and supports a role for Toll-like receptors in PGD pathogenesis. Plasma plasminogen activator inhibitor-1 quantitative trait analysis prioritizes genetic variations in TOLLIP for posttransplant primary graft dysfunction and supports a role for Toll-like receptors in primary graft dysfunction pathogenesis.",
author = "E. Cantu and Y. Suzuki and Diamond, {J. M.} and J. Ellis and J. Tiwari and B. Beduhn and Nellen, {J. R.} and R. Shah and Meyer, {N. J.} and Lederer, {D. J.} and Kawut, {S. M.} and Palmer, {S. M.} and Snyder, {L. D.} and Hartwig, {M. G.} and Lama, {V. N.} and S. Bhorade and M. Crespo and E. Demissie and K. Wille and J. Orens and Shah, {P. D.} and A. Weinacker and D. Weill and D. Wilkes and D. Roe and Ware, {L. B.} and F. Wang and R. Feng and Christie, {J. D.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/ajt.13525",
language = "English (US)",
volume = "16",
pages = "833--840",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk

AU - Cantu, E.

AU - Suzuki, Y.

AU - Diamond, J. M.

AU - Ellis, J.

AU - Tiwari, J.

AU - Beduhn, B.

AU - Nellen, J. R.

AU - Shah, R.

AU - Meyer, N. J.

AU - Lederer, D. J.

AU - Kawut, S. M.

AU - Palmer, S. M.

AU - Snyder, L. D.

AU - Hartwig, M. G.

AU - Lama, V. N.

AU - Bhorade, S.

AU - Crespo, M.

AU - Demissie, E.

AU - Wille, K.

AU - Orens, J.

AU - Shah, P. D.

AU - Weinacker, A.

AU - Weill, D.

AU - Wilkes, D.

AU - Roe, D.

AU - Ware, L. B.

AU - Wang, F.

AU - Feng, R.

AU - Christie, J. D.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The authors previously identified plasma plasminogen activator inhibitor-1 (PAI-1) level as a quantitative lung injury biomarker in primary graft dysfunction (PGD). They hypothesized that plasma levels of PAI-1 used as a quantitative trait could facilitate discovery of genetic loci important in PGD pathogenesis. A two-stage cohort study was performed. In stage 1, they tested associations of loci with PAI-1 plasma level using linear modeling. Genotyping was performed using the Illumina CVD Bead Chip v2. Loci meeting a p <5 × 10-4 cutoff were carried forward and tested in stage 2 for association with PGD. Two hundred ninety-seven enrollees were evaluated in stage 1. Six loci, associated with PAI-1, were carried forward to stage 2 and evaluated in 728 patients. rs3168046 (Toll interacting protein [TOLLIP]) was significantly associated with PGD (p = 0.006). The increased risk of PGD for carrying at least one copy of this variant was 11.7% (95% confidence interval 4.9-18.5%). The false-positive rate for individuals with this genotype who did not have PGD was 6.1%. Variants in the TOLLIP gene are associated with higher circulating PAI-1 plasma levels and validate for association with clinical PGD. A protein quantitative trait analysis for PGD risk prioritizes genetic variations in TOLLIP and supports a role for Toll-like receptors in PGD pathogenesis. Plasma plasminogen activator inhibitor-1 quantitative trait analysis prioritizes genetic variations in TOLLIP for posttransplant primary graft dysfunction and supports a role for Toll-like receptors in primary graft dysfunction pathogenesis.

AB - The authors previously identified plasma plasminogen activator inhibitor-1 (PAI-1) level as a quantitative lung injury biomarker in primary graft dysfunction (PGD). They hypothesized that plasma levels of PAI-1 used as a quantitative trait could facilitate discovery of genetic loci important in PGD pathogenesis. A two-stage cohort study was performed. In stage 1, they tested associations of loci with PAI-1 plasma level using linear modeling. Genotyping was performed using the Illumina CVD Bead Chip v2. Loci meeting a p <5 × 10-4 cutoff were carried forward and tested in stage 2 for association with PGD. Two hundred ninety-seven enrollees were evaluated in stage 1. Six loci, associated with PAI-1, were carried forward to stage 2 and evaluated in 728 patients. rs3168046 (Toll interacting protein [TOLLIP]) was significantly associated with PGD (p = 0.006). The increased risk of PGD for carrying at least one copy of this variant was 11.7% (95% confidence interval 4.9-18.5%). The false-positive rate for individuals with this genotype who did not have PGD was 6.1%. Variants in the TOLLIP gene are associated with higher circulating PAI-1 plasma levels and validate for association with clinical PGD. A protein quantitative trait analysis for PGD risk prioritizes genetic variations in TOLLIP and supports a role for Toll-like receptors in PGD pathogenesis. Plasma plasminogen activator inhibitor-1 quantitative trait analysis prioritizes genetic variations in TOLLIP for posttransplant primary graft dysfunction and supports a role for Toll-like receptors in primary graft dysfunction pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84959505939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959505939&partnerID=8YFLogxK

U2 - 10.1111/ajt.13525

DO - 10.1111/ajt.13525

M3 - Article

AN - SCOPUS:84959505939

VL - 16

SP - 833

EP - 840

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 3

ER -